[go: up one dir, main page]

US20180303868A1 - A teat seal formulation - Google Patents

A teat seal formulation Download PDF

Info

Publication number
US20180303868A1
US20180303868A1 US15/771,884 US201615771884A US2018303868A1 US 20180303868 A1 US20180303868 A1 US 20180303868A1 US 201615771884 A US201615771884 A US 201615771884A US 2018303868 A1 US2018303868 A1 US 2018303868A1
Authority
US
United States
Prior art keywords
formulation
seal formulation
seal
polymer
viscosity
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
US15/771,884
Other versions
US11571442B2 (en
Inventor
Francisco Javier MOLINS ALBANELL
Brendan Gerard SMITH
James Kennedy
Fiona NÍ CHEARÚIL
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Zoetis Broomhill IP Ltd
Original Assignee
Bimeda Research and Development Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Bimeda Research and Development Ltd filed Critical Bimeda Research and Development Ltd
Assigned to BIMEDA RESEARCH & DEVELOPMENT LIMITED reassignment BIMEDA RESEARCH & DEVELOPMENT LIMITED ASSIGNMENT OF ASSIGNORS INTEREST (SEE DOCUMENT FOR DETAILS). Assignors: NÍ CHEARÚIL, Fiona, KENNEDY, JAMES, MOLINS ALBANELL, Francisco Javier, SMITH, Brendan Gerard
Publication of US20180303868A1 publication Critical patent/US20180303868A1/en
Assigned to ZOETIS BROOMHILL IP LIMITED reassignment ZOETIS BROOMHILL IP LIMITED CHANGE OF NAME (SEE DOCUMENT FOR DETAILS). Assignors: BIMEDA RESEARCH & DEVELOPMENT LIMITED
Application granted granted Critical
Publication of US11571442B2 publication Critical patent/US11571442B2/en
Active legal-status Critical Current
Adjusted expiration legal-status Critical

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/74—Synthetic polymeric materials
    • A61K31/765—Polymers containing oxygen
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K33/00—Medicinal preparations containing inorganic active ingredients
    • A61K33/06—Aluminium, calcium or magnesium; Compounds thereof, e.g. clay
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K33/00—Medicinal preparations containing inorganic active ingredients
    • A61K33/14—Alkali metal chlorides; Alkaline earth metal chlorides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/02—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/12—Carboxylic acids; Salts or anhydrides thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/32—Macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. carbomers, poly(meth)acrylates, or polyvinyl pyrrolidone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0041—Mammary glands, e.g. breasts, udder; Intramammary administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents

Definitions

  • This invention relates to a seal formulation for forming a physical barrier in the teat canal.
  • teat sealant containing bismuth subnitrate in a gel base
  • the teat sealant may be used in conjunction with an antibiotic for prophylaxis or treatment of mastitis (GB 2273441A). It is also known to use the teat sealant on its own as a prophylactic treatment to protect against ingress of pathogens during an animal's dry period (WO9826759A).
  • teat seals have been proven to be highly effective over many years.
  • One potential issue however is that if, on completion of the protective period, all of the seal is not fully stripped out of the teat, small amounts of residual teat sealant containing bismuth subnitrate can present during subsequent milkings and can adhere to the milking machine lines.
  • a seal formulation comprising a polymer in a gel base, in the preparation of a medicament for forming a physical barrier in a teat canal for prophylactically controlling infection of a mammary gland in a non-human animal by a mastitis-causing organism, wherein the polymer is a lower alkyl vinyl ether-maleic anhydride copolymer or a salt derivative thereof.
  • a seal formulation for forming a physical barrier in the teat canal of a non-human animal comprising a polymer in a gel base wherein the polymer is a lower alkyl vinyl ether-maleic anhydride copolymer or a salt derivative thereof.
  • the seal is used to treat, prevent or supress infection with a mastitis causing organism.
  • the lower alkyl vinyl ether-maleic anhydride copolymer salt derivative comprises at least one cationic ion including monovalent, bivalent or trivalent cations and mixtures thereof.
  • the cationic ion may be calcium, sodium or mixtures thereof.
  • the polymer is a methyl vinyl ether-maleic anhydride copolymer or a salt derivative thereof.
  • the copolymer may be a mixed calcium and sodium salt derivative of a methyl vinyl ether-maleic anhydride copolymer.
  • the seal formulation contains from 10% to 60% by weight of the polymer.
  • the seal formulation may contain from 20% to 60% by weight of the polymer.
  • the seal formulation may contain from 30% to 55% by weight of the polymer.
  • the seal formulation further comprises a viscosity enhancing agent.
  • the viscosity enhancing agent may comprise zinc oxide.
  • the seal formulation contains from 1% to 35% of the viscosity enhancing agent.
  • the seal formulation may contain from 5% to 25% of the viscosity enhancing agent.
  • the seal formulation may contain from 5% to 20% of the viscosity enhancing agent.
  • the seal formulation further comprises a thixotrophic agent.
  • the seal formulation may contain from 0.1% to 1% of the thixotrophic agent.
  • the seal formulation may contain from 0.4 to 0.8% of the thixotrophic agent.
  • the thixotrophic agent comprises fumed silica.
  • the base is a gel based on aluminium stearate.
  • the base includes liquid paraffin as a vehicle.
  • the seal formulation may contain from 30% to 50% of the base.
  • the lower alkyl vinyl ether-maleic anhydride copolymer and derivative thereof useful in the invention dissolve slowly and contribute adhesive properties as they take up water.
  • Such lower alkyl vinyl ether-maleic acid polymers may be obtained by polymerizing a lower alkyl vinyl ether monomer with maleic anhydride to yield the corresponding lower alkyl vinyl ether-maleic anhydride polymer which is readily hydrolyzable to the acid polymer.
  • the term “lower alkyl” includes C1-C8 alkyl, C1-C6 alkyl, and C1-C4 alkyl. Salt forms of the copolymers can be used.
  • salt forms of the copolymers may be used in which the cationic ion is a monovalent, bivalent, or trivalent cation. Combinations of such salts may also be used.
  • sodium and calcium forms of the copolymer salts and mixtures of such salt forms may be used.
  • a lower alkyl vinyl ether-maleic anhydride copolymer and derivative thereof with a weight average molecular weight of about 200,000 to 2,000,000 is preferably used.
  • GANTREZ MS-955 salt which is available from International Specialty Products.
  • This copolymer has both sodium and calcium salts in one molecule and is supplied as a powder.
  • the copolymer is slowly soluble in water resulting in amber-coloured solutions with high viscosity and adhesion.
  • the divalent calcium ion lightly crosslinks the material through ion bridges to reduce its solubility and increase its cohesive strength and viscoelasticity. It is believed that the repeating units may be represented as:
  • the approximate weight average molecular weight of GANTREZ MS-955 is 1,000,000 and its Brookfield viscosity (mPaS (11.1% solids aq.)) is 700-3000.
  • the formulation includes a thixotrophic agent or rheology modifier or emulsifier.
  • a thixotrophic agent or rheology modifier or emulsifier is fumed silica which is also known as anhydrous colloidal silica. It is available from Evonik under the Trade Name Aerosil. It is also available from Cabot Corporation (Cab-o-sil) and Wacker Chemie—Owens Corning and OCI (Konasil).
  • the formulation also includes Zinc Oxide.
  • Zinc oxide has been used effectively in the treatment of many skin disorders. Zinc oxide has a mild astringent and antiseptic action. Zinc oxide is a Category I skin protector, and promotes healthy skin. Zinc oxide is used for treatment of skin diseases and infections such as eczema, impetigo, ringworm, varicose ulcers, pruritus and psoriasis. It is believed that Zinc oxide regulates the activity of oil glands and is required for protein, DNA and RNA synthesis and collagen and other irritants
  • the invention provides a bio-adhesive teat seal which provides an effective physical barrier to the teat canal of cattle for the prevention of intramammary infections throughout the dry period.
  • FIG. 1 is a bar chart showing comparative analysis between the max injection force and the viscosities of formulations (A) and (E) as well as the control sample;
  • FIG. 2 shows typical adhesive graphs obtained from the bio-adhesion study.
  • the sample is Formulation A (pre-sterilised).
  • Gantrez AN-169 is a water-insoluble white powder.
  • the polymeric anhydride hydrolyses to produce a transparent solution of the free acid.
  • Four standard (AN) grades are available, each differentiated by molecular weight ranging from 200,000 to 2 million.
  • the grade used had a molecular weight of 2,000,000 and the chemical structure is
  • hydrophobic nature of polymer used in a suitable vehicle could be a potential seal.
  • hydrophobic nature of polymer used in a suitable vehicle could be a potential seal.
  • Gantrez MS-955 was also investigated as a potential novel teat sealant system.
  • Gantrez MS-955 polymer is a mixed sodium and calcium salt of methyl vinyl ether and maleic anhydride copolymer that may be synthesised from Gantrez AN169 as follows:
  • Gantrez MS-955 polymer is slowly soluble in water.
  • the divalent calcium ion lightly crosslinks the structure through ion bridges to reduce its solubility and increase its cohesive strength and viscoelasticity.
  • the material has
  • This material has a molecular weight of 1,000,000 and the following chemical structure:
  • Thickened paste (increase in viscosity with addition of water).
  • the samples were stirred at 600 rpm at a temperature of 37° C. for 10 minutes. The heat was then turned off, followed by another 20 minutes of stirring.
  • Samples 1 and 2 were viscous. Sample 1 was chosen and injected into milk. This formed a paste and was placed in an oven at 40° C. After 3 days the sample still held after shaking, however, it has swollen. The sample was removed from the syringe and an adhesive paste remained.
  • Sample 3 and 4 formed a dry paste.
  • petroleum jelly (4 g)
  • sample four gave an injectable paste which was then injected into water and stored at 40° C. After 3 days the samples held after shaking.
  • a syringe was placed in a beaker at 37° C. and allowed to stabilise for ten minutes.
  • the inside of the syringe was wetted and the formulation used in Experiment 6 was utilised.
  • the syringe was submerged in the water and the seal held. Milk was then added and a magnetic flea was introduced at 100 rpm to agitate the syringe to represent teat movement. Over a period of 30 minutes the temperature was monitored.
  • a syringe was placed in a beaker at 37° C. and allowed to stabilise for ten minutes.
  • the inside of the syringe was wetted and the formulation described in Experiment 6 was utilised.
  • the syringe was submerged in the water and the seal held. Milk was then added and a magnetic flea was introduced at 50 rpm to agitate the syringe to represent teat movement.
  • the results are as follows:
  • Time Seal Stability (27-28/5/2013) 5:45-6:00 Stable 6:00-6:15 Stable 6:15-6:30 Stable 3:1-6:45 Stable 6:45-7:00 Stable 7:00-7:15 Stable 7:15-7:30 Stable 7:30-7:45 Stable 7:45-8:00 Stable 8:00-8:00 Stable (28-29/5/2013) 8:00-8:00 Stable (29-30/5/2013) 8:00-8:00 Stable (30-31/5/2013) 8:00-8:00 Stable (31/5/-4/6/2013) 8:00-8:00 Stable (4-5/6/2013) 8:00-8:00 Stable (5-6/6/2013) 8:00-8:00 Stable (6-7/6/2013) 8:00-8:00 Stable (7-10/6/2013) 8:00-8:00 Stable (10-11/6/2013) 8:00-8:00 Stable
  • Formulations were then prepared and consisted of Gantrez MS955 in liquid paraffin/aluminium di-stearate (teat seal base) and Aerosil 200 as an emulsifier/thickening agent. This system formed reliable seals under in vitro conditions and showed no ingress of milk and demonstrated excellent bio-adhesive properties. These formulations were then prepared for gamma sterilisation at 25 kGy after which they were sent for in vivo trials.
  • Aerosil The amount of Aerosil was increased to 1% and 1.5% respectively.
  • Three formulations were prepared for in vivo trials as outlined. Formulation A and B had varying Aerosil concentrations while Formulation C incorporated Zinc oxide. Being hydrophobic in nature, Zinc oxide is a dense material (5.6 g/cm 3 ) and has multiple purposes including viscosity enhancer, antibacterial agent as well as radiopaque properties.
  • the samples were gamma sterilised at 7 kGy, as previous studies showed sterilisation had an effect on the rheological properties of the samples.
  • Aerosil failed to produce a good seal. This could be attributed the “hydrophilic” nature of Aerosil or/and that fact that a good seal is concentration dependent. [Aerosil concentrations above 0.8% previously displayed a significant change in viscosity].
  • the ratio of active (Gantrez/Zinc Oxide) to the TS Base appears to be very important in achieving a good seal. Lowering the Gantrez concentration may lead to loss in the bio-adhesive nature of the formulation. In addition the use of TS base works well at low concentrations when used as emollient, however, increasing the amount beyond 50% leads to a greasy or oilier paste. This in turn will have a negative effect on bio-adhesive nature of the seal.
  • Typical bases included liquid paraffin oil and 1-Oleoyl-rac-glycerol, while three metal oxides were examined namely Zirconium Oxide, Titanium Dioxide and Zinc Oxide. Variations of the Gantrez, Metal Oxides and base were formulated and evaluated.
  • a Lloyd LRX tensile tester was employed in compression mode with a load cell of 2500N to measure the force required to express a formulation from the syringe, the samples were tested at room temperature. Initially tests were carried out on empty syringes to measure the distance travelled by the plunger within the. A distance of 60 mm was obtained from measuring samples from the top of the barrel to the top of the plunger. The distance travelled by the plunger within the barrel of the syringe was found to be 47.5 mm. A test was designed to accommodate the syringe and machine set. Eight formulations in total were prepared each with varying concentration and components. The force required to express each paste was measured a minimum of 5 times.
  • the max load force between the samples was investigated. There were no significant differences between the samples. However, sterilisation has altered the flow properties of the formulation. In relation to the work at the max load, the Bimeda Boviseal sample is significantly larger when compared to the other formulations and this is due to the higher density of the Bismuth which requires more energy upon formula delivery.
  • the aim of this study was to determine the radiopaque quality or limit of detection of formulations at various concentrations of active (Zinc Oxide). X-Ray images were taken of each sample. A metal circular coin was placed in the images as a marker.
  • Gantrez MS-955 polymer is a mixed sodium and calcium salt of methyl vinyl ether and maleic anhydride copolymer supplied as a powder.
  • the polymer is slowly soluble in water resulting in amber-coloured solutions with high viscosity and adhesion.
  • the divalent calcium ion lightly crosslinks the material through ion bridges to reduce its solubility and increase its cohesive strength and viscoelasticity. It is believed that the repeating units may be represented as:
  • hydrolysis One such abiotic process is hydrolysis.
  • a common kind of hydrolysis is that of a salt of a weak acid or base. Water spontaneously ionizes into hydroxide anions and hydrogen cations. The salt too dissociates into its constituent anions and cations. In this particular case Na+ and an ester. An Hydrogen ion reacts with ester to produce an acid product while cations react slowly but very little with hydroxide
  • Esters are chemical compounds consisting of a carbonyl adjacent to an ether linkage. They are derived by reacting an oxoacid with a hydroxyl compound such as an alcohol or phenol. Therefore, any such polyols for example glycerol will react with acid groups in Gantrez post hydrolysis thereby producing an ester with increased viscosity. The esterification reaction is both slow and reversible.
  • the equation for the reaction between an acid RCOOH and an alcohol R′OH (where R and R′ can be the same or different) is:
  • the process for preparation of an adhesive teat seal firstly involved mixing the specified amount of mixed salt of PVA/MA (Gantrez) (bio-adhesive polymer) co-polymer with an emulsifier namely Aerosil 200 and Zinc Oxide. All additives are slowly agitated until uniformly dispersed.
  • the final stage involved adding a wetting agent or emollient either liquid paraffin or TS base (alugel based liquid paraffin while continuously agitating the mixture). Whilst manufacturing procedure is carried out in that order, it is not limited to that order. In fact on scaling up it may be of benefit to slowly add the Gantrez last into an oil based dispersion in order to control the rate of reaction. This step is of particular importance if using Gantrez S97 powder.
  • the objective of this process is to induce a heating reaction to catalyse chemical crosslinking.
  • Formulation was made by first placing polyol (glycerol) in a main vessel. Gantrez MS 955 is added to the polyol, while heating to 75° C.; and is mixed until uniform. At 70-75° C., Aerosil is added and the composition and mixed until uniform, adjusting agitation to facilitate good turnover. The vessel is removed from heat and with moderate agitation; the Zinc Oxide followed immediately by liquid paraffin oil is added with continuous stirring throughout addition of reactants. Mixing is continued at a lower level of agitation until uniform. The resulting product is a paste-like with excellent spreadable and bio-adhesives properties.
  • the ratio of active (Gantrez/Zinc Oxide) to the TS Base appears to be important in achieving a good seal. Lowering the Gantrez concentration may lead to loss in the bio-adhesive nature of formulation.
  • the use of teat seal base works well at low concentrations when used as emollient, however, increasing the amount beyond 50% leads to greasy or oilier paste. This in turn will have a negative effect on bio-adhesive nature of the seal.
  • a formulation having high density/viscosity is required. However, if the viscosity is too high there is decreased compliance or easy application of teat seal. There are 4 additives which appear to have an influence on the viscosity of formulations;

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Inorganic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

A seal formulation for forming a physical barrier in the teat canal of a non-human animal for prophylactically controlling infection of a mammary gland by a mastitis-causing organism comprises a polymer in a gel base wherein the polymer is a lower alkyl vinyl ether-maleic anhydride copolymer or a salt derivative thereof. The lower alkyl vinyl ether-maleic anhydride copolymer salt derivative may comprise at least one cationic ion including monovalent, bivalent or trivalent cations and mixtures thereof.

Description

    INTRODUCTION
  • This invention relates to a seal formulation for forming a physical barrier in the teat canal.
  • An intra-mammary teat sealant containing bismuth subnitrate in a gel base is known. The teat sealant may be used in conjunction with an antibiotic for prophylaxis or treatment of mastitis (GB 2273441A). It is also known to use the teat sealant on its own as a prophylactic treatment to protect against ingress of pathogens during an animal's dry period (WO9826759A).
  • These known teat seals have been proven to be highly effective over many years. One potential issue however is that if, on completion of the protective period, all of the seal is not fully stripped out of the teat, small amounts of residual teat sealant containing bismuth subnitrate can present during subsequent milkings and can adhere to the milking machine lines.
  • It is a challenge to provide a teat sealant which can be readily formulated, delivered into the teat canal, which will form an effective seal whilst being reliably stripped out of the teat canal when no longer required.
    • STATEMENTS OF INVENTION
  • According to the invention there is provided use of a seal formulation, comprising a polymer in a gel base, in the preparation of a medicament for forming a physical barrier in a teat canal for prophylactically controlling infection of a mammary gland in a non-human animal by a mastitis-causing organism, wherein the polymer is a lower alkyl vinyl ether-maleic anhydride copolymer or a salt derivative thereof.
  • According to the invention there is also provided a seal formulation for forming a physical barrier in the teat canal of a non-human animal comprising a polymer in a gel base wherein the polymer is a lower alkyl vinyl ether-maleic anhydride copolymer or a salt derivative thereof. The seal is used to treat, prevent or supress infection with a mastitis causing organism.
  • In one embodiment the lower alkyl vinyl ether-maleic anhydride copolymer salt derivative comprises at least one cationic ion including monovalent, bivalent or trivalent cations and mixtures thereof. The cationic ion may be calcium, sodium or mixtures thereof.
  • In one case the polymer is a methyl vinyl ether-maleic anhydride copolymer or a salt derivative thereof.
  • The copolymer may be a mixed calcium and sodium salt derivative of a methyl vinyl ether-maleic anhydride copolymer.
  • In one embodiment the seal formulation contains from 10% to 60% by weight of the polymer. The seal formulation may contain from 20% to 60% by weight of the polymer. The seal formulation may contain from 30% to 55% by weight of the polymer.
  • In one embodiment the seal formulation further comprises a viscosity enhancing agent. The viscosity enhancing agent may comprise zinc oxide. In one case the seal formulation contains from 1% to 35% of the viscosity enhancing agent. The seal formulation may contain from 5% to 25% of the viscosity enhancing agent. The seal formulation may contain from 5% to 20% of the viscosity enhancing agent.
  • In one embodiment the seal formulation further comprises a thixotrophic agent. The seal formulation may contain from 0.1% to 1% of the thixotrophic agent. The seal formulation may contain from 0.4 to 0.8% of the thixotrophic agent. In one case the thixotrophic agent comprises fumed silica.
  • In one embodiment the base is a gel based on aluminium stearate.
  • In one case the base includes liquid paraffin as a vehicle. The seal formulation may contain from 30% to 50% of the base.
  • The lower alkyl vinyl ether-maleic anhydride copolymer and derivative thereof useful in the invention dissolve slowly and contribute adhesive properties as they take up water. Such lower alkyl vinyl ether-maleic acid polymers may be obtained by polymerizing a lower alkyl vinyl ether monomer with maleic anhydride to yield the corresponding lower alkyl vinyl ether-maleic anhydride polymer which is readily hydrolyzable to the acid polymer. The term “lower alkyl” includes C1-C8 alkyl, C1-C6 alkyl, and C1-C4 alkyl. Salt forms of the copolymers can be used. For example, salt forms of the copolymers may be used in which the cationic ion is a monovalent, bivalent, or trivalent cation. Combinations of such salts may also be used. In particular, sodium and calcium forms of the copolymer salts and mixtures of such salt forms may be used.
  • A lower alkyl vinyl ether-maleic anhydride copolymer and derivative thereof with a weight average molecular weight of about 200,000 to 2,000,000 is preferably used.
  • One example of such a polymer is GANTREZ MS-955 salt which is available from International Specialty Products. This copolymer has both sodium and calcium salts in one molecule and is supplied as a powder. The copolymer is slowly soluble in water resulting in amber-coloured solutions with high viscosity and adhesion. The divalent calcium ion lightly crosslinks the material through ion bridges to reduce its solubility and increase its cohesive strength and viscoelasticity. It is believed that the repeating units may be represented as:
  • Figure US20180303868A1-20181025-C00001
  • The approximate weight average molecular weight of GANTREZ MS-955 is 1,000,000 and its Brookfield viscosity (mPaS (11.1% solids aq.)) is 700-3000.
  • The formulation includes a thixotrophic agent or rheology modifier or emulsifier. One such is fumed silica which is also known as anhydrous colloidal silica. It is available from Evonik under the Trade Name Aerosil. It is also available from Cabot Corporation (Cab-o-sil) and Wacker Chemie—Owens Corning and OCI (Konasil).
  • The formulation also includes Zinc Oxide.
  • Zinc oxide has been used effectively in the treatment of many skin disorders. Zinc oxide has a mild astringent and antiseptic action. Zinc oxide is a Category I skin protector, and promotes healthy skin. Zinc oxide is used for treatment of skin diseases and infections such as eczema, impetigo, ringworm, varicose ulcers, pruritus and psoriasis. It is believed that Zinc oxide regulates the activity of oil glands and is required for protein, DNA and RNA synthesis and collagen and other irritants
  • The invention provides a bio-adhesive teat seal which provides an effective physical barrier to the teat canal of cattle for the prevention of intramammary infections throughout the dry period.
  • An effective teat seal of the invention has the following properties
      • Non toxic, biocompatible, and capable of being sterilised.
      • Persistent—the seal should remain in situ for the duration of the dry cow period
      • Consistency—the seal should not break up within the teat
      • Ease of removal—at the end of the dry period the seal should be easily removable from the udder and not give rise to persistent residues of the seal
      • If an antibiotic is used in association with the seal, the seal should be compatible with the antibiotic formulation.
      • Radiopaque
      • Ease of delivery
    BRIEF DESCRIPTION OF THE FIGURES
  • FIG. 1 is a bar chart showing comparative analysis between the max injection force and the viscosities of formulations (A) and (E) as well as the control sample; and
  • FIG. 2 shows typical adhesive graphs obtained from the bio-adhesion study. The sample is Formulation A (pre-sterilised).
    •  DETAILED DESCRIPTION
  • The invention will be more clearly understood from the following description thereof given by way of example only.
  • Gantrez AN-169
  • Gantrez AN-169, is a water-insoluble white powder. The polymeric anhydride hydrolyses to produce a transparent solution of the free acid. Four standard (AN) grades are available, each differentiated by molecular weight ranging from 200,000 to 2 million.
  • Various Grades of the Gantrez AN Product Range
  • Typical
    Properties AN-119 AN-903 AN-139 AN-169
    Appearance White, free- White, free- White, free- White, free-
    flowing flowing flowing flowing
    powder powder powder powder
    Approx. Mw 200,000 800,000 1,000,000 2,000,000
    Brookfield 15 30 40 85
    Viscosity,
    mPa · S
    5%/10% solids 35 100 145 1400
    (Hydrolized)
  • The grade used had a molecular weight of 2,000,000 and the chemical structure is
  • Figure US20180303868A1-20181025-C00002
    • Chemical Structure of Gantrez AN-169 Experiment 1
  • 4 g of the polymer was added to 10 ml of water and stirred
  • Outcome: Did not dissolve
  • 4 g of the polymer was added to 10 ml of Milk and stirred
  • Outcome: Did not dissolve
  • Conclusion: The hydrophobic nature of polymer used in a suitable vehicle could be a potential seal.
    • Experiment 2
  • 1 g of the polymer was added to 1 ml of water and stirred
  • Outcome: Did not dissolve—formed a paste
  • 1 g of the polymer was added to 2 ml of water and stirred
  • Outcome: Formed a viscous paste, felt lubricious
  • Conclusion: The hydrophobic nature of polymer used in a suitable vehicle could be a potential seal.
  • Gantrez MS-955
  • An alternative polymer, MS-955, was also investigated as a potential novel teat sealant system. Gantrez MS-955 polymer is a mixed sodium and calcium salt of methyl vinyl ether and maleic anhydride copolymer that may be synthesised from Gantrez AN169 as follows:
  • Figure US20180303868A1-20181025-C00003
  • Reaction Outlining the Formation of Gantrez MS 955
  • Alternative derivatives of this polymer can be manufactured by substituting various salt systems in the reaction as follows:
  • Figure US20180303868A1-20181025-C00004
  • Reaction Outlining the Formation of a Tailored Mixed Sodium/Zinc Salt Copolymer
  • Gantrez MS-955 polymer is slowly soluble in water. The divalent calcium ion lightly crosslinks the structure through ion bridges to reduce its solubility and increase its cohesive strength and viscoelasticity. The material has
      • excellent wet adhesive strength;
      • long-lasting hold; and
      • mucoadhesive that enables delivery to mucous membranes
  • This material has a molecular weight of 1,000,000 and the following chemical structure:
  • Figure US20180303868A1-20181025-C00005
    • Chemical Structure of Gantrez MS-955 Experiment 3—Initial Solution Trials at Room Temperature
  • 4 g of the polymer Gantrez MS-955 was added to 10 ml of deionised water and stirred.
  • Outcome: Dissolved and formed a paste (semi-solid).
  • 4 g of the polymer was added to 10 ml of Milk and stirred.
  • Outcome: Dissolved and formed an adhesive paste.
  • Conclusion: The polymer reacted with the milk and an adhesive paste was produced.
    • Experiment 4—Distilled Water as a Delivery Mechanism
  • 2 g of the polymer was added to 3 ml of water and stirred (600 rpm) at room temperature.
  • Outcome: Dissolved and formed a paste.
  • 30 ml of distilled water was further added in stages to the solution and stirred.
  • Outcome: Thickened paste (increase in viscosity with addition of water).
  • Conclusion: Using distilled water as the delivery mechanism was not ideal as it made a very viscous paste, causing difficulty with injection.
    • Experiment 5—Liquid Paraffin as a Delivery Mechanism
  • 2 g of the polymer was added to 3 ml of liquid paraffin and stirred (600 rpm) at room temperature.
  • Outcome: Encapsulated and formed a gel when injected, however it took a long time to do so.
    • Experiment 6—Ethanol as a Delivery Mechanism
  • 3 g of the polymer was added to 2 ml of ethanol and stirred at 600 rpm at 37° C.
  • Outcome: viscous solution.
  • 2 g of the polymer was further added to the solution and stirred.
  • Outcome: Thickened solution to form an injectable paste.
  • Conclusion: Initial trial with the syringe was a success relative to flowability.
    • Experiment 7—Optimise Ethanol Formulation
  • The following formulations were prepared.
  • Formulation Utilising Ethanol as a Delivery Vehicle
  • 1 2 3 4
    Polymer/ Polymer/Ethanol Polymer/Ethanol Polymer/Ethanol
    Ethanol
    50/50 60/40 70/30 80/20
    3 g/3 ml 3.6 g/2.4 ml 4.2 g/1.8 ml 4.8 g/1.2 ml
  • The samples were stirred at 600 rpm at a temperature of 37° C. for 10 minutes. The heat was then turned off, followed by another 20 minutes of stirring.
  • Outcome: Samples 1 and 2 were viscous. Sample 1 was chosen and injected into milk. This formed a paste and was placed in an oven at 40° C. After 3 days the sample still held after shaking, however, it has swollen. The sample was removed from the syringe and an adhesive paste remained.
  • Outcome: Sample 3 and 4 formed a dry paste. On addition of petroleum jelly (4 g), to sample four gave an injectable paste which was then injected into water and stored at 40° C. After 3 days the samples held after shaking.
  • Conclusion: Petroleum jelly has shown promise as a delivery mechanism.
    • Experiment 8—Investigate Petroleum Jelly as a Delivery Mechanism
  • 5 g of petroleum jelly was heated to 60° C. (melt) and stirred at 600 rpm. 4 g of the polymer was gently added to the solution. The heat was turned off and the sample was allowed to stir for 30 30 minutes until cool.
  • Outcome: An injectable paste was formed and was subsequently injected into both water and milk. After 3 days (40° C.) the samples held after shaking. The sample was then removed after three days and a swollen adhesive paste remained.
  • Conclusion: Gantrez MS-955 reacted with the milk and an adhesive paste was produced.
    • Experiment 9—Stability Analysis Over a Temperature Range
  • A syringe was placed in a beaker at 37° C. and allowed to stabilise for ten minutes. The inside of the syringe was wetted and the formulation used in Experiment 6 was utilised. The syringe was submerged in the water and the seal held. Milk was then added and a magnetic flea was introduced at 100 rpm to agitate the syringe to represent teat movement. Over a period of 30 minutes the temperature was monitored.
  • TABLE 1
    Temperature versus seal stability
    Temperature (° C.) Seal Stability
    37 Stable
    42 Stable
    47 Stable
    52 Stable
    57 Stable
    60 Failure after 10 minutes
  • Outcome: Stability was obtainable until the temperature reached 60° C.
  • Conclusion: This is a promising formulation and the failure at high temperature was probably due to melting of the petroleum jelly
    • Experiment 10—Stability Analysis at a Constant Temperature
  • A syringe was placed in a beaker at 37° C. and allowed to stabilise for ten minutes. The inside of the syringe was wetted and the formulation described in Experiment 6 was utilised. The syringe was submerged in the water and the seal held. Milk was then added and a magnetic flea was introduced at 50 rpm to agitate the syringe to represent teat movement. The results are as follows:
  • TABLE 2
    Time versus seal stability
    Time Seal Stability
    (27-28/5/2013) 5:45-6:00 Stable
    6:00-6:15 Stable
    6:15-6:30 Stable
    6:30-6:45 Stable
    6:45-7:00 Stable
    7:00-7:15 Stable
    7:15-7:30 Stable
    7:30-7:45 Stable
    7:45-8:00 Stable
    8:00-8:00 Stable
    (28-29/5/2013) 8:00-8:00 Stable
    (29-30/5/2013) 8:00-8:00 Stable
    (30-31/5/2013) 8:00-8:00 Stable
    (31/5/-4/6/2013) 8:00-8:00 Stable
    (4-5/6/2013) 8:00-8:00 Stable
    (5-6/6/2013) 8:00-8:00 Stable
    (6-7/6/2013) 8:00-8:00 Stable
    (7-10/6/2013) 8:00-8:00 Stable
    (10-11/6/2013) 8:00-8:00 Stable
  • Outcome: The seal was stable. To calculate the oscillation (which represents extreme teat movement) the magnet flea moved the syringe through a repeated cycle time. This was calculated based on the number of cycles completed per 10 seconds. The average results were calculated as shown below.
  • TABLE 3
    Calculation of cycle time
    Cycle Times
    1 2 3 4 5 6 7 8 9 10
    Time(Sec) 10 10 10 10 10 10 10 10 10 10 Average
    Cycles 17 18 18 17 16 17 17 16 17 17 17
  • Therefore,
  • Average 17 cycles per 10 Sec
      • 102 cycles per 1 min
      • 6,102 cycles per 1 hour
  • Thus, over a 14 hour period, there were 85,428 cycles (24 hours 146,880)
  • Conclusion: The formulation held under constant temperature and repeated oscillation. After 15 days the sample was removed and ejected. The compound contained the swollen matrix.
  • Objective: Stability test under a volume load.
    • Experiment 11—Stability Analysis at a Constant Temperature
  • The formulation from Experiment 6 was removed from the oven after 5 hours and placed under a volume of 3.5 litres of water.
  • TABLE 4
    Stability analysis under load
    Time Seal Stability
    (27-28/5/2013) 5:00-8:00 Stable
    (28-29/5/2013) 8:00-8:00 Stable
    (29-30/5/2013) 8:00-8:00 Stable
    (30-31/5/2013) 8:00-8:00 Stable
    (31/5/-4/6/2013) 8:00-8:00 Stable
    (4-7/6/2013) 8:00-8:00 Stable
    (7-10/6/2013) 8:00-8:00 Stable
    (10-11/6/2013) 8:00-8:00 Stable
    (11-12/6/2013) 8:00-8:00 Stable
    (12-14/6/2013) 8:00-8:00 Stable
    (14-17/6/2013) 8:00-8:00 Stable
    (17-19/6/2013) 8:00-8:00 Stable
    (19/6-04/7/2013) 8:00-8:00 Stable (46 days)
    (4/7-12/7/2013) 8:00-8:00 Stable (54 days)
    (12/7-15/7/2013) 8:00-8:00 Stable (57 days) Finish
  • Outcome: The formulation has shown no signs of degrading. The seal held for 57 days.
  • Conclusion: This formulation has shown promise both in milk at 37° C. and under volume.
  • In Vivo Trial 1
  • Formulations were then prepared and consisted of Gantrez MS955 in liquid paraffin/aluminium di-stearate (teat seal base) and Aerosil 200 as an emulsifier/thickening agent. This system formed reliable seals under in vitro conditions and showed no ingress of milk and demonstrated excellent bio-adhesive properties. These formulations were then prepared for gamma sterilisation at 25 kGy after which they were sent for in vivo trials.
  • TABLE 5
    Percentage formulations used in vivo trials
    Formulation
    A B
    % W/W TS Base 49.6 49.7
    % W/W Gantrez 49.6 49.7
    % W/W Aerosil 200 0.8 0.6
    Ratio: Active:Base 1:1 1:1
  • Two cows were infused, one containing the 0.6 Aerosil (coded 50:50(0.6)) and the other the 0.8 Aerosil (coded 50:50(0.8)). An antimicrobial was also infused with the formulations (Kefamast) and the findings are presented below:
  • TABLE 6
    Results from the in vivo trials
    Day 1 Day 6
    Infused Cow 1 after the last
    milking of her lactation as
    follows: Cow 1-Formulation 50:50(0.8)
    Front Right: Kefamast and Front Right: Boviseal stripped out completely
    Boviseal
    Front Left: Kefamast and Front Left: formulation 50:50(0.8) seemed to strip out well
    formulation 50:50(0.8)
    Rear Right: Kefamast and Rear Right: No formulation 50:50(0.8) was visibly
    formulation 50:50(0.8) present
    Rear Left: Kefamast and Rear Left: Slight granules of formulation 50:50(0.8)
    formulation 50:50(0.8) could be felt lining the teat duct
    Infused cow 2 after the last
    milking of her lactation as
    follows: Cow 2 - Formulation 50:50(0.6)
    Front Right: Kefamast and Front Right: Boviseal stripped out completely
    Boviseal
    Front Left: Kefamast and Front Left: no formulation 50:50(0.6) was palpably
    formulation 50:50(0.6) left in the teat and milk was all that was seemingly
    stripped out
    Rear Right: Kefamast and Rear Right: Slight granules of formulation 50:50(0.6)
    formulation 50:50(0.6) could be felt lining the teat duct but not visible
    Rear Left: Kefamast and Rear Left: no formulation 50:50(0.6) was palpably
    formulation 50:50(0.6) left in the teat and milk was all that was obviously
    stripped out
  • The strength of the teat seal appeared to be dependent on Aerosil concentration with 0.8% Aerosil holding a seal in the front teat for 3 days during the in vivo trials. The 0.6% left a gelatinous residue once stripped from teat. In addition, studies undertaken displayed a relationship between Aerosil concentration and the viscosity measured. This relationship is temperature dependent with exponential behaviour visible at 20° C. while a linear relationship occurred at 37° C. The rheological data is presented in Table 7.
  • TABLE 7
    Rheology of the 50-50 Gantrez: TS oil base
    Post-
    Pre-Sterilisation Post-Sterilisation Pre-Sterilisation Sterilisation
    Viscosity (Pas) at Viscosity (Pas) at Viscosity (Pas) Viscosity (Pas)
    20° C. 20° C. at 37° C. at 37° C.
    0.8% 257.5 165.1 170.3 184.7
    Aerosil
    274.9 150.9 224.5 213
    256.5 118.6 251 189.4
    Average 262.96 144.86 215.26 195.7
    STV 8.45 19.46 33.58 12.38
    0.6% 211 147.3 178.2 190.1
    Aerosil
    230.6 154.1 209 218.2
    221.4 137.2 187.7 171.6
    Average 221 146.2 191.63 193.3
    STV 8 6.94 12.87 19.15
    Pre Post Pre Post
    20° C. 20° C. % difference 37° C. 37° C. % difference
    0.8 262.96 144.86 −44.91 215.26 195.7 −9.09
    0.6 221 146.2 −33.85 191.63 193.3 0.87
  • In Vivo Trial 2 The trial was repeated and the 50:50(0.8) sample was removed; however, there was no notable trace of the formulation present in the rear of the udder where 60% of the milk is carried. Neither cow showed any ill-effects during or in the few days after the study ended.
  • In Vivo Trial 3
  • The amount of Aerosil was increased to 1% and 1.5% respectively. Three formulations were prepared for in vivo trials as outlined. Formulation A and B had varying Aerosil concentrations while Formulation C incorporated Zinc oxide. Being hydrophobic in nature, Zinc oxide is a dense material (5.6 g/cm3) and has multiple purposes including viscosity enhancer, antibacterial agent as well as radiopaque properties. For this trial, the samples were gamma sterilised at 7 kGy, as previous studies showed sterilisation had an effect on the rheological properties of the samples.
  • TABLE 8
    Percentage formulations used in vivo trials
    Formulation
    A B C
    % W/W TS Base 51.48 59.1 39.7
    % W/W Gantrez 47.52 39.4 43
    % W/W Aerosil 1 1.5 0.8
    200
    % W/W ZnO N/A N/A 16.55
    Ratio: Active:Base 0.92:1.08 1:1.5 1.5:1
  • TABLE 9
    Rheology results pre-sterilisation
    PRE-STERILISATION
    Formulation Temperature Viscosity Formulation Temperature Viscosity Formulation Temperature Viscosity
    A 20° C. 618.8 B 20° C. 609.6 C 20° C. 630.3
    A 20° C. 535.6 B 20° C. 510 C 20° C. 542.7
    A 20° C. 576.2 B 20° C. 544.5 C 20° C. 598.4
    Average 576.8667 Average 554.7 Average 590.4667
    SDV 33.96953 SDV 41.29625 SDV 36.19985
    A 37° C. 376.3 B 37° C. 181.9 C 37° C. 339.4
    A 37° C. 417.1 B 37° C. 244.7 C 37° C. 317.5
    A 37° C. 380.1 B 37° C. 306.4 C 37° C. 389.2
    Average 391.1667 Average 244.3333 Average 348.7
    SDV 18.40314 SDV 50.82757 SDV 30.001
  • TABLE 10
    Rheology results post sterilisation
    POST-STERILISATION
    Formulation Temperature Viscosity Formulation Temperature Viscosity Formulation Temperature Viscosity
    A 20° C. 545.1 B 20° C. 551.1 C 20° C. 687.6
    A 20° C. 583 B 20° C. 575.8 C 20° C. 710.1
    A 20° C. 610.3 B 20° C. 566.4 C 20° C. 621.6
    Average 579.4667 Average 564.4333 Average 673.1
    SDV 26.73479 SDV 10.17917 SDV 37.55662
    A 37° C. 360.1 B 37° C. 356.6 C 37° C. 403.8
    A 37° C. 366.4 B 37° C. 384.5 C 37° C. 430.2
    A 37° C. 372.6 B 37° C. 369.2 C 37° C. 441.1
    Average 366.3667 Average 370.1 Average 425.0333
    SDV 5.103158 SDV 11.40789 SDV 15.65979
  • All three formulations were infused into cows. After a 5 day period, each formulation was stripped out from the back teat, where milk production is more significant. A small amount of Formulation A was retrieved. Formulation B was not present and Formulation C was successfully removed.
  • Increasing concentration of Aerosil failed to produce a good seal. This could be attributed the “hydrophilic” nature of Aerosil or/and that fact that a good seal is concentration dependent. [Aerosil concentrations above 0.8% previously displayed a significant change in viscosity].
  • The ratio of active (Gantrez/Zinc Oxide) to the TS Base appears to be very important in achieving a good seal. Lowering the Gantrez concentration may lead to loss in the bio-adhesive nature of the formulation. In addition the use of TS base works well at low concentrations when used as emollient, however, increasing the amount beyond 50% leads to a greasy or oilier paste. This in turn will have a negative effect on bio-adhesive nature of the seal.
  • The introduction of ZnO led to a successful teat seal. ZnO appears to react with Gantrez giving a swollen structure on removal. The degree of swelling itself may be cause for excellent teat seal.
  • Following irradiation at 7 kGy the viscosity of Formulation C with Zinc Oxide increased at both 20 and 37 degrees Celsius. This is indicative of chemical binding/crosslinking of the Zinc Oxide and Gantrez and potentially is the foundation of a superior teat seal.
  • Gantrez/Metallic Oxide Formulation Development
  • From the trial described above, the synergistic mixture of the Gantrez based polymer with the Zinc Oxide shows promise. To achieve a better understanding of the interactions between the Gantrez and the metallic viscosity/rheometry studies as well as compression testing were employed to characterise the formulations. This was completed in conjunction with previous work by taking metallic oxides of similar densities and integrating them into predetermined formulations. A range of formulations were then prepared by varying both the composition and concentrations of the various constituents in order to determine their effect on both viscosity and ease of administration (compression testing). The base was also changed to test its effect on the ease of administration, with the emphasis being on the structural effects of composition dependency. Typical bases included liquid paraffin oil and 1-Oleoyl-rac-glycerol, while three metal oxides were examined namely Zirconium Oxide, Titanium Dioxide and Zinc Oxide. Variations of the Gantrez, Metal Oxides and base were formulated and evaluated.
  • TABLE 11
    Viscosity and Injection Force results
    Composition Results
    Gantrez Viscosity Max
    Testing MS955 Metal oxide Base Additive (Pa · S) Load/Force
    Sample (%) (%) (%) (%) @ 20° C. (Newton)*
    SEAL N/A N/A N/A Aerosil 70.00 32.908
    Formulation
    A
    25 Zinc Oxide liquid Aerosil 399.36 35.38
    25 Paraffin 0.5
    49.5
    B 25 Zirconium liquid Aerosil 37.04 27.03
    Oxide Paraffin 0.5
    25 49.5
    C 25 Titanium liquid Aerosil 130.43 89.792
    Dioxide Paraffin 0.5
    25 49.5
    D 20 Zinc Oxide liquid Aerosil 464.76 41.35
    30 Paraffin 0.5
    49.5
    E 30 Zinc Oxide liquid Aerosil 241.37 41.33
    20 Paraffin 0.5
    49.5
    F 25 Zinc Oxide 1-Oleoyl- Aerosil 23.03 38.86
    25 rac-glycerol 0.5
    49.5
    G 34.4 Zinc Oxide 1-Oleoyl- Aerosil 92.68 113.01
      34.4 rac-glycerol 0.4
    30.8
    H 29.75 Zinc Oxide liquid Aerosil 1450 64.22
      29.75 Paraffin 0.5
    40.0
  • From the above results it appears that viscosity and ease of administration are not related and is solely composition dependant. For example, Formulation A, B and C are all similar in composition and concentration except each formulation contains a different metal oxide (each metal oxide had similar densities). Zirconium Dioxide yields the lowest viscosity and the max force load needed to express sample was 27 Newton. However, in spite of Titanium Dioxide and Zinc Oxide yielding a viscosity of 140 and 413 Pa·s respectively, the Zinc Oxide formulation was substantially easier to express. These results indicate composition is a primary factor to characterise the ease of administration. The use of 1-Oleoyl-rac-glycerol in place of liquid paraffin resulted in change in viscosity from 413 to 23 Pa·s. However, the formulation was substantially harder to express. The higher the Zinc Oxide concentration in the 1-Oleoyl-rac-glycerol based systems the harder the formulations were to express.
  • Large differences in the viscosity and the force required to express the various formulations indicated that the viscosity is not a measure or related indirectly to the difficulty of expressing a sample from a syringe (unless all formulations utilise the same constituents). In addition all of the metal oxides have similar densities of around 5 g/cm3; however, Zirconium Dioxide is known for been chemically un-reactive and this is further substantiated by Formulation B which provided a viscosity of 37 Pa·s. In contrast, Zinc Oxide yielded a viscosity of 413 Pa·s and this is a result of chemical interactions with the Gantrez, which subsequently progressed to crosslinking within the formulation; thus increasing the viscosity. A viscosity of 130 Pa·s was found for Titanium Dioxide which is indicative of physical interactions, mainly due to the polarity of the molecule. Based on the formulations, four samples were selected. It was decided to further investigate two particular formulations, namely (A) and (E).
  • A trial was devised to examine Formulations (A) and (E) exposed to two sterilisation cycles (7 and 25 kGy).
  • Rheological Analysis of Formulations (A) and (E)
  • A large reduction in the viscosity post sterilisation was evident in all samples.
  • On analysing the rheological results, a 54% reduction in viscosity for Formulation (A) occurred at 20° C. when the samples were sterilised at 7 KGy. By increasing the temperature to 37° C., the viscosity decreased from 219.53 to 66.07 Pa·s (69.9% reduction). When Formulation (A) was sterilised at 25 KGy, once again, the viscosities decreased at both test temperatures (see Table 30). Overall, there was a reduction of 81% in the viscosity from the pre-sterilised sample at 20° C. to the post sterilised 7 KGy sample tested at 37° C. When the 25 KGy samples were evaluated, a 75% reduction in the viscosity was noted.
  • This reduction in the viscosity is perceived to be a result of the chemical scission of the crosslinks via gamma exposure. Similar findings were found in Formulation (E). However, a 68% reduction was noted in the viscosity for the pre-sterilised samples tested at 20° C. to the post sterilised samples at 37° C. Considering Formulation (E) had a 5% lower concentration of ZnO compared to (A), it would suggest that reducing the concentration of ZnO would be beneficial. The concentration of ZnO used in the in vivo trial is believed to be a contributing factor in the breakdown of the formulation.
  • TABLE 12
    Viscosity evaluation of Formulation (A) and (E)
    Post
    Pre (7KGy) %
    20° C. 20° C. difference
    A 351.25 160.32 −54.36
    E 266.62 110.46 −58.57
    Post
    Pre (7KGy) %
    37° C. 37° C. difference
    A 219.53 66.07 −69.90
    E 174.08 85.31 −50.99
    Post (25
    Pre KGy) %
    20° C. 20° C. difference
    A 351.25 122.1  −65.24
    E 266.62 89.12 −66.57
    Post (25
    Pre KGy) %
    37° C. 37° C. difference
    A 219.53 86.07 −60.79
    E 174.08 85.13 −51.10
    Pre Post (7KGy) %
    20° C. 37° C. difference
    A 351.25 66.07 −81.19
    E 266.62 85.31 −68.00
    Post
    Pre (25KGy) %
    20° C. 37° C. difference
    A 351.25 86.07 −75.50
    E 266.62 85.13 −68.07
  • Evaluation of the Administration of Formulation (A) and (E) from a Syringe
  • Based on the test, comparative analysis on the compression/injection force from the syringes was evaluated. A Lloyd LRX tensile tester was employed in compression mode with a load cell of 2500N to measure the force required to express a formulation from the syringe, the samples were tested at room temperature. Initially tests were carried out on empty syringes to measure the distance travelled by the plunger within the. A distance of 60 mm was obtained from measuring samples from the top of the barrel to the top of the plunger. The distance travelled by the plunger within the barrel of the syringe was found to be 47.5 mm. A test was designed to accommodate the syringe and machine set. Eight formulations in total were prepared each with varying concentration and components. The force required to express each paste was measured a minimum of 5 times.
  • The time taken as well as the formulation content has an overall effect on the administration force. This was more evident in the Bimeda Boviseal formulation, where an injection time of 5.7 seconds had a max force of 61N compared to a 34N force when administered at 9.5 seconds. The difference is explained by the higher density of the Bismuth present in the Bimeda formulation which upon the application of a high shear (faster injection time), packs the material at the front of the nozzle. Thus, more force is required to push the formulation through the channel of the nozzle. A slower time allows the material to flow much easier and as a result this reduces the max force of insertion. Formulations (A) and (E) were more consistent during the time trials but did exhibit varying injection profiles.
  • Taking a standard injection speed of 300 mm/min (9.5 sec), the max load (force) between the samples was investigated. There were no significant differences between the samples. However, sterilisation has altered the flow properties of the formulation. In relation to the work at the max load, the Bimeda Boviseal sample is significantly larger when compared to the other formulations and this is due to the higher density of the Bismuth which requires more energy upon formula delivery.
  • In relation to the sterilised samples, the ratio of Gantrez to ZnO appears to be very important as this can alter both the viscosity and injection force requirements. In the case of Formulation (A) which has a 25%/25% Gantrez/ZnO component, dose rates of both 7 and 25 KGy reduced the viscosity of the samples. However, a 7 KGy dose rate decreased the injection force in contrast to the 25 KGy which increased the injection force. The inverse is true for Formulation (E), which has a 30%/20% Gantrez/ZnO component. Although there are two flow properties being evaluated (viscosity and injection force), the thixotropic nature of the formulations behaves differently under shear conditions. FIG. 1 illustrates the effects of viscosity is noticeable compared to the Max Injection forces.
  • Bio-Adhesion Analysis
  • Bio-adhesion studies were carried out to evaluate the adhesive nature of the formulations. The Instrument was a Texture Analyser from Stable Micro Systems and a predetermined program was selected which was based on the measurement of an adhesive gum. The instrument was calibrated with a 1000 g weight and a 92% confidence interval was obtained using a P/36R-aluminium Probe. A typical graph obtained from the work is presented in FIG. 2. The main findings are as follows:
      • Mixing formulations with milk displayed bio-adhesive properties. However, this was not visible in formulations which did not have the milk present as well as the particular grade of Gantrez used.
      • All formulations increased in bio-adhesiveness with Gantrez concentration.
      • Greater adhesive properties seen after sterilisation.
      • Form X had good adhesive properties
  • TABLE 13
    Formulations used in the Bio-adhesion study (1)
    Gantrez Zinc oxide Aerosil
    Sample (%) (%) Base (%) (%) Additive
    Original 59.5 N/A 39.7 0.8 N/A
    Form C 43 16.5 39.7 0.8 N/A
    Form X
    25 25 32.8 0.5 16.7% of 1-Oleoyl-
    rac-glycerol
    Form A 25 25 49.5 0.5 N/A
    Form E 30 20 49.5 0.5 N/A
  • A second Bio-adhesion Study was carried out to evaluate alternative to the Gantrez MS955.
  • TABLE 14
    Formulations used in the Bio-adhesion study (2)
    liquid
    Zinc paraffin Aerosil Additive
    Formulation Gantrez oxide (%) oil (%) (%) (%)
    F MS955 40% 10 49.5 0.5 N/A
    G AN169 20.5% 14 62 0.5 N/A
    H Gantrez S97-P 20 49.5 0.5 N/A
    30%
  • The main findings are as follows;
      • Formulation F: Paste like with no noticeable adhesive properties.
      • Formulation G: Very adhesive on appearance also due to its high molecular weight, as less polymer was needed.
      • Formulation H: Non-adhesive in appearance. However, there was an apparent increase in viscosity when left overnight.
  • Each of the above formulations were then mixed with 2 ml of milk to mimic in vivo conditions and then bio-adhesion was retested.
      • Formulation F: Increase in elasticity following mixing with milk. The formulation had good adhesion and cohesiveness and did not break up.
      • Formulation G: An increase in time and shear was required to form a paste. This was less viscous and it was apparent that no crosslinking occurred.
      • Formulation H: Extremely adhesive (most adhesive formulation to date), did not break up. However, it was difficult to express the formulation from syringes.
  • Each of pure Gantrez polymers were also tested with milk and the findings are;
      • MS955 with 4 ml milk . . . v adhesive
  • AN169 with 4 ml milk . . . not miscible with milk insoluble no reaction
      • MS97-P with 4 ml milk . . . adhesive properties visible
  • Radiopacity Testing
  • The aim of this study was to determine the radiopaque quality or limit of detection of formulations at various concentrations of active (Zinc Oxide). X-Ray images were taken of each sample. A metal circular coin was placed in the images as a marker.
  • TABLE 15
    Formulations used in the Radiopacity study
    Formulation (%)
    1 2 3
    Gantrez MS955 30 40 45
    Zinc Oxide 20 10 5
    Aerosil 0.5 0.5 0.5
    Liquid Paraffin 49.5 49.5 49.5
  • An X-ray image of a pure sample of Gantrez MS955 was taken for comparative purposes. Due to low density of the polymer, poor radiopaque visibility was witnessed. The three formulations made by varying the concentration of Zinc Oxide which has a density of 5.61 g/cm3 were tested. From the images, a clear pattern emerged whereby the higher the concentration of Zinc Oxide, the darker or easier the image is detected by X-ray. However, at concentrations as low as 5%, Zinc Oxide is still apparent in the images, which could be beneficial in formulation design.
  • Other Metal Oxides
      • To test the hypothesis that Zinc Oxide (ZnO) was reacting with the Gantrez, a number of similar Metal Oxides with comparable densities was chosen for analysis. Keeping with the same concentration, each Metal Oxide was substituted into the same base formula. Zirconium Dioxide is known to be chemically un-reactive and this is further substantiated by Formulation B (refer to table 11) which yielded a viscosity of 37 Pa·s compared to Zinc Oxide which yielded a viscosity of 413 Pa·s. This shows that the ZnO reacted with the Gantrez which subsequently progressed to crosslinking within the formulation; thus increasing the viscosity. Titanium Dioxide yielded a viscosity of 130 Pa·s which is indicative of the physical interactions, mainly due to the polarity of the molecule.
      • The reduction in the viscosity is postulated to be a result of the chemical scission of the crosslinked structure via gamma exposure. Similar findings were found in Formulation (E), however, a 68% reduction was noted. Considering Formulation (E) had a 5% lower concentration of ZnO compared to (A), it would suggest that reducing the concentration of ZnO would be beneficial. Only one formulation (E7) was deemed recoverable from the animals, but this was not consistent. The concentration of ZnO used in vivo trial 5 is considered to be a contributing factor in the breakdown of the formulation.
      • In relation to sterilisation, the ratio of Gantrez to ZnO is very important. Looking at Formulation (A) which has a 25%/25% Gantrez/ZnO component, dose rates of both 7 and 25 KGy reduced the viscosity of the samples. With regard to the injection administration study, a 7 KGy dose rate decreased the injection force. In contrast, the 25 KGy exposure to Formulation (A) increased the injection force. The inverse is true for Formulation (E), which has a 30%/20% Gantrez/ZnO composition. Thus, it's worth noting that the thixotropic nature of the formulations behaves differently under shear conditions. It is for this reason such variability exists and further optimisation will be required in working out the optimal Gantrez/ZnO ratios in a desired base under set gamma dose rates.
      • Mixing formulations which contained the MS955 grade of Gantrez with milk displayed bio-adhesive properties.
      • All formulations increased in bio-adhesiveness with Gantrez concentration.
      • Greater adhesive properties seen after sterilisation.
      • At concentrations as low as 5%, Zinc Oxide is still apparent in the radiopaque images, which could be beneficial in formulation design.
  • Chemical Reactions
  • Gantrez MS955
  • Gantrez MS-955 polymer is a mixed sodium and calcium salt of methyl vinyl ether and maleic anhydride copolymer supplied as a powder. The polymer is slowly soluble in water resulting in amber-coloured solutions with high viscosity and adhesion. The divalent calcium ion lightly crosslinks the material through ion bridges to reduce its solubility and increase its cohesive strength and viscoelasticity. It is believed that the repeating units may be represented as:
  • Figure US20180303868A1-20181025-C00006
  • Chemical Repeat Unit of Gantrez MS955 outlining the Calcium Ions
  • Therefore, in the presence of Milk, in vivo or an aqueous environment two reactions will occur:
    • a) Calcium bridging will lightly crosslink the structure, thus increasing elasticity, adhesiveness and viscosity.
    • b) Bronsted lowry acid base theory; Gantrez MS-955 is not readily biodegradable but will slowly degrade to simple carbon compounds through biological and abiotic processes.
  • One such abiotic process is hydrolysis. A common kind of hydrolysis is that of a salt of a weak acid or base. Water spontaneously ionizes into hydroxide anions and hydrogen cations. The salt too dissociates into its constituent anions and cations. In this particular case Na+ and an ester. An Hydrogen ion reacts with ester to produce an acid product while cations react slowly but very little with hydroxide

  • NaC2H3O2+H2O==>NaOH+HC2H3O2

  • Na++C2H3O2 −+H2O==>Na++OH−+HC2H3O2
      • Since NaOH is a strong base it breaks up and yields OH−, the salt is basic.
      • HC2H3O2 is a weak acid and will form (does not break up in water).
  • Reactions Among Excipients and Gantrez within the Formulations
  • 1) Bronsted Lowry Acid Base Theory
      • Zinc Oxide is an amphoteric oxide and therefore can act as both an acid and base. Once Gantrez has reverted to carboxylic acid, Zinc Oxide will react to form a salt and water. (ZNO is degraded by most acids).

  • ZnO+2CH3COOH==>(CH3COO)2Zn+H2O
      • Note ZnO will also react slowly with fatty acids in oils (1-Oleoyl-rac-glycerol) to produce the corresponding carboxylates, such as oleate or stearate.
  • 2) Esterification
  • Esters are chemical compounds consisting of a carbonyl adjacent to an ether linkage. They are derived by reacting an oxoacid with a hydroxyl compound such as an alcohol or phenol. Therefore, any such polyols for example glycerol will react with acid groups in Gantrez post hydrolysis thereby producing an ester with increased viscosity. The esterification reaction is both slow and reversible. The equation for the reaction between an acid RCOOH and an alcohol R′OH (where R and R′ can be the same or different) is:
  • Figure US20180303868A1-20181025-C00007
  • Equation for the Reaction Between an Acid RCOOH and an Alcohol R′OH
  • Manufacturing Process 1
  • The process for preparation of an adhesive teat seal firstly involved mixing the specified amount of mixed salt of PVA/MA (Gantrez) (bio-adhesive polymer) co-polymer with an emulsifier namely Aerosil 200 and Zinc Oxide. All additives are slowly agitated until uniformly dispersed. The final stage involved adding a wetting agent or emollient either liquid paraffin or TS base (alugel based liquid paraffin while continuously agitating the mixture). Whilst manufacturing procedure is carried out in that order, it is not limited to that order. In fact on scaling up it may be of benefit to slowly add the Gantrez last into an oil based dispersion in order to control the rate of reaction. This step is of particular importance if using Gantrez S97 powder.
  • Note: Continuous stirring should be used once liquid paraffin added.
  • Mixing Equipment used: Heildolph Mixer at 200 rpm
  • Hotplate with magnetic stirrer or manually stirred on small scale
  • Manufacturing Process 2
  • The objective of this process is to induce a heating reaction to catalyse chemical crosslinking. Formulation was made by first placing polyol (glycerol) in a main vessel. Gantrez MS 955 is added to the polyol, while heating to 75° C.; and is mixed until uniform. At 70-75° C., Aerosil is added and the composition and mixed until uniform, adjusting agitation to facilitate good turnover. The vessel is removed from heat and with moderate agitation; the Zinc Oxide followed immediately by liquid paraffin oil is added with continuous stirring throughout addition of reactants. Mixing is continued at a lower level of agitation until uniform. The resulting product is a paste-like with excellent spreadable and bio-adhesives properties.
  • TABLE 16
    Percentage formulations used to prepare Formulation C
    Formulation
    C
    % W/W TS Base 39.7
    % W/W Gantrez 43
    % W/W Aerosil 200 0.8
    % W/W ZNO 16.55
    Ratio: Active:Base 1.5:1
  • The ratio of active (Gantrez/Zinc Oxide) to the TS Base appears to be important in achieving a good seal. Lowering the Gantrez concentration may lead to loss in the bio-adhesive nature of formulation. The use of teat seal base works well at low concentrations when used as emollient, however, increasing the amount beyond 50% leads to greasy or oilier paste. This in turn will have a negative effect on bio-adhesive nature of the seal.
  • A formulation having high density/viscosity is required. However, if the viscosity is too high there is decreased compliance or easy application of teat seal. There are 4 additives which appear to have an influence on the viscosity of formulations;
      • Zinc oxide
      • Aerosil
      • Gantrez
      • Alugel in Base
  • By varying these concentrations in the formulation as shown in Table 17, it is expected that a seal with all of the desired characteristics can be achieved. Gamma sterilisation chemically and physically alters the structure of the formulation. Chain scission may occur as a result of irradiation which is reflected by the reduction in viscosity of the materials. Gamma sterilisation may also induce crosslinking and this may be used to manipulate the formulation.
  • TABLE 17
    Proposed range of additives
    Material Proposed range (%)
    Gantrez MS955 30-55
    Zinc Oxide  5-20
    Aerosil 0.4-0.8
    Base 30-50
  • The invention is not limited to the embodiments hereinbefore described, which may be varied in detail.

Claims (21)

1-40. (canceled)
41. A seal formulation for forming a physical barrier in the teat canal of a non-human animal comprising a polymer in a gel base wherein the polymer is a lower alkyl vinyl ether-maleic anhydride copolymer or a salt derivative thereof.
42. A seal formulation as claimed in claim 41 wherein the lower alkyl vinyl ether-maleic anhydride copolymer salt derivative comprises at least one cationic ion including monovalent, bivalent or trivalent cations and mixtures thereof.
43. A seal formulation as claimed in claim 42 wherein the cationic ion is calcium, sodium or mixtures thereof.
44. A seal formulation as claimed in claim 41 wherein the polymer is a methyl vinyl ether-maleic anhydride copolymer or a salt derivative thereof.
45. A seal formulation as claimed in claim 41 wherein the copolymer is a mixed calcium and sodium salt derivative of a methyl vinyl ether-maleic anhydride copolymer.
46. A seal formulation as claimed in claim 41 wherein the seal formulation contains from 10% to 60% by weight of the polymer.
47. A seal formulation as claimed in claim 41 wherein the seal formulation contains from 20% to 60% by weight of the polymer.
48. A seal formulation as claimed in claim 41 wherein the seal formulation contains from 30% to 55% by weight of the polymer.
49. A seal formulation as claimed in claim 41 which further comprises a viscosity enhancing agent.
50. A seal formulation as claimed in claim 49 wherein the viscosity enhancing agent comprises zinc oxide.
51. A seal formulation as claimed in claim 49 wherein the seal formulation contains from 1% to 35% of the viscosity enhancing agent.
52. A seal formulation as claimed in claim 49 wherein the seal formulation contains from 5% to 25% of the viscosity enhancing agent.
53. A seal formulation as claimed in claim 49 wherein the seal formulation contains from 5% to 20% of the viscosity enhancing agent.
54. A seal formulation as claimed in claim 41 which further comprises a thixotrophic agent.
55. A seal formulation as claimed in claim 54 wherein the seal formulation contains from 0.1% to 1% of the thixotrophic agent.
56. A seal formulation as claimed in claim 54 wherein the seal formulation contains from 0.4 to 0.8% of the thixotrophic agent.
57. A seal formulation as claimed in claim 54 wherein the thixotrophic agent comprises fumed silica.
58. A seal formulation as claimed in claim 41 wherein the base is a gel based on aluminium stearate.
59. A seal formulation as claimed in claim 41 wherein the base includes liquid paraffin as a vehicle.
60. A seal formulation as claimed in claim 41 wherein the seal formulation contains from 30% to 50% of the base.
US15/771,884 2015-10-29 2016-10-19 Teat seal formulation Active 2037-06-24 US11571442B2 (en)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
EP15192207 2015-10-29
EP15192207.7 2015-10-29
EP15192207 2015-10-29
PCT/EP2016/075044 WO2017071998A1 (en) 2015-10-29 2016-10-19 A teat seal formulation

Publications (2)

Publication Number Publication Date
US20180303868A1 true US20180303868A1 (en) 2018-10-25
US11571442B2 US11571442B2 (en) 2023-02-07

Family

ID=54427574

Family Applications (1)

Application Number Title Priority Date Filing Date
US15/771,884 Active 2037-06-24 US11571442B2 (en) 2015-10-29 2016-10-19 Teat seal formulation

Country Status (9)

Country Link
US (1) US11571442B2 (en)
EP (1) EP3368082B1 (en)
AU (1) AU2016345400B2 (en)
CA (1) CA3003938A1 (en)
ES (1) ES2830199T3 (en)
HU (1) HUE052523T2 (en)
PL (1) PL3368082T3 (en)
PT (1) PT3368082T (en)
WO (1) WO2017071998A1 (en)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2018280866A1 (en) * 2017-06-09 2019-12-12 Zoetis Broomhill Ip Limited Intramammary veterinary composition
AU2024233862A1 (en) * 2023-03-06 2025-09-04 Welfare Concepts Limited Teat sealant composition and method of preventing mastitis

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5750591A (en) * 1996-02-29 1998-05-12 The Block Drug Company Denture adhesive containing partial zirconium, calcium, sodium gantrez salt
US20050191270A1 (en) * 2004-02-27 2005-09-01 Hydromer, Inc. Anti-infectious hydrogel compositions
WO2010065747A2 (en) * 2008-12-04 2010-06-10 Merial Limited Intramammary teat sealant
US20140222067A1 (en) * 2013-02-01 2014-08-07 Xcede Technologies, Inc. Minimally invasive surgery, including vascular closure, and associated sealants

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4393080A (en) * 1981-12-24 1983-07-12 E. R. Squibb & Sons, Inc. Adhesive compositions
US5093387A (en) 1989-12-21 1992-03-03 Warner-Lambert Company Denture adhesive
CA2097078C (en) 1990-11-27 2003-02-11 Virgil F. Pichierri Diaper rash treatment
DK0673239T3 (en) 1992-12-08 1999-03-22 Bimeda Res Dev Ltd Aqueous antibiotic composition for veterinary use
ES2183223T5 (en) 1996-12-18 2015-05-07 Bimeda Research & Development Limited Intra-mammary composition for veterinary use that does not contain anti-inflammatory agents
US6166102A (en) * 1998-12-08 2000-12-26 Block Drug Company, Inc. Denture adhesive
US6800671B1 (en) * 2000-04-21 2004-10-05 Britesmile, Inc. Low peak exotherm curable compositions
EP1572123A4 (en) * 2002-12-20 2010-07-21 Glaxosmithkline Llc Denture adhesive
US20070149642A1 (en) * 2005-12-28 2007-06-28 Sunstar, Inc. Denture fixative composition
US7906138B2 (en) 2006-10-10 2011-03-15 Wisconsin Alumni Research Foundation Intra-mammary teat sealant formulation and method of using same to reduce or eliminate visual defects in aged cheeses

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5750591A (en) * 1996-02-29 1998-05-12 The Block Drug Company Denture adhesive containing partial zirconium, calcium, sodium gantrez salt
US20050191270A1 (en) * 2004-02-27 2005-09-01 Hydromer, Inc. Anti-infectious hydrogel compositions
WO2010065747A2 (en) * 2008-12-04 2010-06-10 Merial Limited Intramammary teat sealant
US20140222067A1 (en) * 2013-02-01 2014-08-07 Xcede Technologies, Inc. Minimally invasive surgery, including vascular closure, and associated sealants

Also Published As

Publication number Publication date
HUE052523T2 (en) 2021-05-28
EP3368082A1 (en) 2018-09-05
AU2016345400B2 (en) 2021-10-14
US11571442B2 (en) 2023-02-07
PT3368082T (en) 2020-11-11
CA3003938A1 (en) 2017-05-04
WO2017071998A1 (en) 2017-05-04
AU2016345400A1 (en) 2018-05-24
ES2830199T3 (en) 2021-06-03
PL3368082T3 (en) 2021-03-22
EP3368082B1 (en) 2020-09-23

Similar Documents

Publication Publication Date Title
US10729698B2 (en) Sol-gel polymer composites and uses thereof
JP6525952B2 (en) Biocompatible hydrogel polymer matrix for cell delivery
US20200237956A1 (en) Homogeneous Aqueous Solution of Injectable Chitosan
EP3612155A1 (en) Veterinary compositions for use in treating mastitis, and associated methods
TW201737925A (en) A pharmaceutical composition useful for preventing adhesion or hemostasis
US9901662B2 (en) Adhesion preventing material
JP5725607B2 (en) Dental treatment composition
US11571442B2 (en) Teat seal formulation
WO2014123225A1 (en) Livestock nipple pack composition, livestock nipple pack, livestock composite nipple pack kit, and method for protecting nipple of livestock
JP2016002072A (en) Livestock teat pack material, livestock teat pack composition, and method for protecting teat of livestock
JP6433826B2 (en) Nipple pack material for livestock, and mastitis prevention method for dairy livestock
JP2014168451A (en) Livestock nipple pack and composition for forming the same, as well as method for protecting nipple of livestock
JP2015186472A (en) Nipple pack material for livestock

Legal Events

Date Code Title Description
FEPP Fee payment procedure

Free format text: ENTITY STATUS SET TO UNDISCOUNTED (ORIGINAL EVENT CODE: BIG.); ENTITY STATUS OF PATENT OWNER: LARGE ENTITY

AS Assignment

Owner name: BIMEDA RESEARCH & DEVELOPMENT LIMITED, IRELAND

Free format text: ASSIGNMENT OF ASSIGNORS INTEREST;ASSIGNORS:MOLINS ALBANELL, FRANCISCO JAVIER;SMITH, BRENDAN GERARD;KENNEDY, JAMES;AND OTHERS;SIGNING DATES FROM 20180531 TO 20180812;REEL/FRAME:047222/0177

STPP Information on status: patent application and granting procedure in general

Free format text: DOCKETED NEW CASE - READY FOR EXAMINATION

AS Assignment

Owner name: ZOETIS BROOMHILL IP LIMITED, IRELAND

Free format text: CHANGE OF NAME;ASSIGNOR:BIMEDA RESEARCH & DEVELOPMENT LIMITED;REEL/FRAME:047308/0413

Effective date: 20180629

STPP Information on status: patent application and granting procedure in general

Free format text: NON FINAL ACTION MAILED

STPP Information on status: patent application and granting procedure in general

Free format text: RESPONSE TO NON-FINAL OFFICE ACTION ENTERED AND FORWARDED TO EXAMINER

STPP Information on status: patent application and granting procedure in general

Free format text: FINAL REJECTION MAILED

STPP Information on status: patent application and granting procedure in general

Free format text: ADVISORY ACTION MAILED

STCV Information on status: appeal procedure

Free format text: ON APPEAL -- AWAITING DECISION BY THE BOARD OF APPEALS

STCV Information on status: appeal procedure

Free format text: BOARD OF APPEALS DECISION RENDERED

STPP Information on status: patent application and granting procedure in general

Free format text: DOCKETED NEW CASE - READY FOR EXAMINATION

STPP Information on status: patent application and granting procedure in general

Free format text: NON FINAL ACTION MAILED

STPP Information on status: patent application and granting procedure in general

Free format text: RESPONSE TO NON-FINAL OFFICE ACTION ENTERED AND FORWARDED TO EXAMINER

STPP Information on status: patent application and granting procedure in general

Free format text: NOTICE OF ALLOWANCE MAILED -- APPLICATION RECEIVED IN OFFICE OF PUBLICATIONS

STPP Information on status: patent application and granting procedure in general

Free format text: PUBLICATIONS -- ISSUE FEE PAYMENT VERIFIED

STCF Information on status: patent grant

Free format text: PATENTED CASE

CC Certificate of correction